Literature DB >> 24883236

Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.

Jane T Seto1, Niclas E Bengtsson1, Jeffrey S Chamberlain1.   

Abstract

Duchenne muscular dystrophy (DMD) is an inherited, progressive muscle wasting disorder caused by mutations in the dystrophin gene. An increasing variety of approaches are moving towards clinical testing that all aim to restore dystrophin production and to enhance or preserve muscle mass. Gene therapy methods are being developed to replace the defective dystrophin gene or induce dystrophin production from mutant genes. Stem cell approaches are being developed to replace lost muscle cells while also bringing in new dystrophin genes. This review summarizes recent progress in the field with an emphasis on clinical applications.

Entities:  

Keywords:  Duchenne muscular dystrophy; adeno-associated viral vectors; antisense oligonucleotide; cxmd dog; dystrophin; gene therapy; inducible pluripotent stem cell; mdx mouse; mesoangioblast; morpholino; myoblast; pericyte; premature termination codon; satellite cell; stem cells; utrophin

Year:  2014        PMID: 24883236      PMCID: PMC4036820          DOI: 10.1007/s40124-014-0044-x

Source DB:  PubMed          Journal:  Curr Pediatr Rep


  103 in total

Review 1.  The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions.

Authors:  Margaret Buckingham; Frédéric Relaix
Journal:  Annu Rev Cell Dev Biol       Date:  2007       Impact factor: 13.827

2.  Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques.

Authors:  Guangping Gao; Lawrence T Bish; Meg M Sleeper; Xin Mu; Lan Sun; You Lou; Jiachuan Duan; Chunyan Hu; Li Wang; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2011-06-24       Impact factor: 5.695

3.  Direct isolation of satellite cells for skeletal muscle regeneration.

Authors:  Didier Montarras; Jennifer Morgan; Charlotte Collins; Frédéric Relaix; Stéphane Zaffran; Ana Cumano; Terence Partridge; Margaret Buckingham
Journal:  Science       Date:  2005-09-01       Impact factor: 47.728

4.  Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.

Authors:  M Manuvakhova; K Keeling; D M Bedwell
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

5.  Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy.

Authors:  Francesco Saverio Tedesco; Mattia F M Gerli; Laura Perani; Sara Benedetti; Federica Ungaro; Marco Cassano; Stefania Antonini; Enrico Tagliafico; Valentina Artusi; Emanuela Longa; Rossana Tonlorenzi; Martina Ragazzi; Giorgia Calderazzi; Hidetoshi Hoshiya; Ornella Cappellari; Marina Mora; Benedikt Schoser; Peter Schneiderat; Mitsuo Oshimura; Roberto Bottinelli; Maurilio Sampaolesi; Yvan Torrente; Vania Broccoli; Giulio Cossu
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

6.  Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin.

Authors:  Glen B Banks; Ariana C Combs; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2008-09-16       Impact factor: 6.150

Review 7.  Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Authors:  Annemieke Aartsma-Rus; Ivo Fokkema; Jan Verschuuren; Ieke Ginjaar; Judith van Deutekom; Gert-Jan van Ommen; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

8.  Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.

Authors:  Aurélie Goyenvalle; Arran Babbs; Jordan Wright; Vivienne Wilkins; Dave Powell; Luis Garcia; Kay E Davies
Journal:  Hum Mol Genet       Date:  2012-03-02       Impact factor: 6.150

9.  Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human.

Authors:  Marcella Neri; Silvia Torelli; Sue Brown; Isabella Ugo; Patrizia Sabatelli; Luciano Merlini; Pietro Spitali; Paola Rimessi; Francesca Gualandi; Caroline Sewry; Alessandra Ferlini; Francesco Muntoni
Journal:  Neuromuscul Disord       Date:  2007-09-07       Impact factor: 4.296

10.  The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Julaine M Florence; Michelle Eagle; Eduard Gappmaier; Allan M Glanzman; Robert Spiegel; Jay Barth; Gary Elfring; Allen Reha; Stuart Peltz
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

View more
  17 in total

Review 1.  The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Authors:  Anandita Agarwala; Peter Jones; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

2.  Dystrophin's central domain forms a complex filament that becomes disorganized by in-frame deletions.

Authors:  Olivier Delalande; Anne-Elisabeth Molza; Raphael Dos Santos Morais; Angélique Chéron; Émeline Pollet; Céline Raguenes-Nicol; Christophe Tascon; Emmanuel Giudice; Marine Guilbaud; Aurélie Nicolas; Arnaud Bondon; France Leturcq; Nicolas Férey; Marc Baaden; Javier Perez; Pierre Roblin; France Piétri-Rouxel; Jean-François Hubert; Mirjam Czjzek; Elisabeth Le Rumeur
Journal:  J Biol Chem       Date:  2018-03-13       Impact factor: 5.157

3.  Quantifying disease activity in fatty-infiltrated skeletal muscle by IDEAL-CPMG in Duchenne muscular dystrophy.

Authors:  Ami Mankodi; Courtney A Bishop; Sungyoung Auh; Rexford D Newbould; Kenneth H Fischbeck; Robert L Janiczek
Journal:  Neuromuscul Disord       Date:  2016-07-28       Impact factor: 4.296

4.  An Evidence-Based, Community-Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials.

Authors:  Rebecca R Moultrie; Megan A Lewis; Ryan S Paquin; Ann Lucas; Jill Jarecki; Holly L Peay
Journal:  J Genet Couns       Date:  2017-12-20       Impact factor: 2.537

Review 5.  Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.

Authors:  Michael E Nance; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2015-10-15       Impact factor: 5.695

Review 6.  Viral vector-mediated gene therapies.

Authors:  Katrin Hollinger; Jeffrey S Chamberlain
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 7.  Genome engineering: a new approach to gene therapy for neuromuscular disorders.

Authors:  Christopher E Nelson; Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Nat Rev Neurol       Date:  2017-09-29       Impact factor: 42.937

8.  Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders.

Authors:  Holly L Peay; Barbara B Biesecker; Benjamin S Wilfond; Jill Jarecki; Kendall L Umstead; Diana M Escolar; Aad Tibben
Journal:  Clin Trials       Date:  2018-02-23       Impact factor: 2.486

9.  A reporter mouse for optical imaging of inflammation in mdx muscles.

Authors:  Leonel Martinez; Natalia V Ermolova; Tomo-O Ishikawa; David B Stout; Harvey R Herschman; Melissa J Spencer
Journal:  Skelet Muscle       Date:  2015-04-30       Impact factor: 4.912

10.  Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.

Authors:  Giulio Cossu; Stefano C Previtali; Sara Napolitano; Maria Pia Cicalese; Francesco Saverio Tedesco; Francesca Nicastro; Maddalena Noviello; Urmas Roostalu; Maria Grazia Natali Sora; Marina Scarlato; Maurizio De Pellegrin; Claudia Godi; Serena Giuliani; Francesca Ciotti; Rossana Tonlorenzi; Isabella Lorenzetti; Cristina Rivellini; Sara Benedetti; Roberto Gatti; Sarah Marktel; Benedetta Mazzi; Andrea Tettamanti; Martina Ragazzi; Maria Adele Imro; Giuseppina Marano; Alessandro Ambrosi; Rossana Fiori; Maria Pia Sormani; Chiara Bonini; Massimo Venturini; Letterio S Politi; Yvan Torrente; Fabio Ciceri
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.